Global Hemp Group Inc. (CSE: GHG) (FRA: GHG) (OTC: GBHPF) Aims to be a Leader in the Multi-Faceted Industrial Hemp Market

Industrial hemp is the only commodity that has the potential to generate revenue from multiple finished goods in the global food, construction materials, nutraceutical, textile and bio-energy industries
Global Hemp Group completed hemp trials last year which set the stage for a full-fledged commercial hemp operation in New Brunswick, Canada, in 2018
Under Canadian law, CBD will become legal to extract from Industrial Hemp in July 2018
Hemp Business Journal estimates that the hemp industry will grow to $1.8 billion in sales by 2020, led by hemp food, body care, and CBD-based products
Official data demonstrates that the hemp industry is growing rapidly, at a 22 percent five-year CAGR, and is being led by food and body care products, with hemp CBD products showing a 53 percent AGR

Global Hemp Group, Inc. (CSE: GHG) (FRANKFURT: GHG) (OTC: GBHPF) is just beginning to scratch the surface of what will over time become a robust market for the production of raw materials and a variety of wholesale products and consumer goods developed from the non-psychoactive industrial varieties of the species Cannabis sativa L.

Global Hemp Group intends to establish and develop a portfolio of companies interlinked in the production of hemp, from its initial cultivation to wholesale materials delivered to product developers and distributors.

Through joint ventures and acquisitions, GHG is focused on cannabinoid production, with medium-term plans to operate in the automotive, building materials, bio-composites, food, nutritional supplements and nutraceuticals markets. The company is guided by the overarching theme of ‘global environmental stewardship’. Global Hemp Group intends to apply key concepts of sustainability and social responsibility in all of the markets that it enters.

With a successful hemp cultivation trial last year, GHG and joint venture partner Marijuana Company of America, Inc. (OTC: MCOA) have set the stage for development of the first commercial hemp operation on the Acadian peninsula of New Brunswick, Canada, in over 20 years.

Cannabinoids

With the expected legalization of recreational cannabis and the extraction of cannabinoids from industrial hemp in mid to late 2018, the partnership expects to begin cannabinoid extraction from a minimum of 125 acres of hemp grown this year in New Brunswick, Canada. The company is also discussing partnerships for straw processing to create building materials following the October harvest this year, with a medium- to long-term plan of building permanent processing facilities by the fall of 2019.

GHG is also pursuing hemp cultivation and extraction opportunities in the U.S. Pacific Northwest, with the goal of operating in both the Canadian and United States hemp markets.

Industrial Solutions

GHG seeks to establish an operating strategy it refers to as the Hemp Agro-Industrial Zone (“HAIZ”) (http://cnw.fm/A4Iqr), which will be focused on building a platform of cooperation between farmers, labor, technology and capital across all industrial hemp sectors to create collective value for shareholders. All parts of the plant are to be utilized with the HAIZ concept, including the production of CBD and other cannabinoid-based wholesale products from the flowers and leaves, cottonized fibers from the straw, building materials from the hurd (woody core) and oils and cakes from the grain.

Construction

A number of companies have begun producing hempcrete blocks that deliver a durable product that retains thermal mass and has a low carbon footprint when it comes to energy usage (http://cnw.fm/Ch3uq). They could also potentially reduce building material costs by 50 percent or more when cultivated, processed and constructed on site. Hempcrete has thermal qualities that preserve optimal indoor temperatures year-round in a wide variety of regions and climates. In addition, it is mold free, pest free and fireproof.

A Washington state company is retrofitting homes with hemp;
A Colorado company completed the state’s first permitted “hempcrete” structure in October (http://cnw.fm/9C8qF);
This Asheville, North Carolina, hemp home is one of four hemp homes constructed in the state (http://cnw.fm/oTs06);
Israel’s first hemp house was built last March on Mount Carmel;
Canada’s JustBioFiber constructed a house on Vancouver Island using an interlocking Lego-like hemp block, and there are hundreds of hempcrete buildings across Canada;
In Britain, five hempcrete homes were built in 2017 alone;
France has been constructing buildings with hemp for decades;
South Africa has promoted this hemp home as Africa’s most sustainable building (http://cnw.fm/NYA1v).

Bio-Composites

There are more than 10 million cars on the road that use hemp bio-composites for door panels, dashboards, consoles, carpeting and even brake pads. Mercedes, BMW and Lotus have been using hemp in their vehicle construction for many years (http://cnw.fm/J3Qjd). Auto manufacturers find that hemp auto parts lower vehicle weight and therefore improve gas mileage. Glass fiber used to make the body of a Chevrolet Corvette could easily be replaced with hemp fiber and be stronger and more resilient. Henry Ford knew in the 1940s that natural bio-composites could replace heavier metals used in auto manufacturing (http://cnw.fm/FtJ0k) and be lighter and stronger than traditional materials.

In Conclusion

It has been proven that hemp can be a sustainable alternative for many traditional materials used throughout history.

Hemp is the only plant on Earth that can feed, clothe, house, fuel and medicate humanity. Hemp is potentially the most industrially usable biomass produced over the shortest growth cycle, utilizing the least amount of water, nutrients and pesticides, while sequestering the greatest level of carbon. It is one of the few plants on the planet that can be grown commercially almost anywhere in the world.

For more information, visit the company’s website at www.GlobalHempGroup.com

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP): IP Portfolio, Licensing and R&D are Keys to Growth in 2018

LXRP has global patents or patents-pending in more than 40 countries, including the U.S., Australia, China, the European Union and Canada
Company is working through a C$250,000 budget for an 18-month collaborative research agreement with the National Research Council
Licensing is a revenue generator, with LXRP offering to license its disruptive DehydraTECH™ technology in countries where it is patented or patent-pending

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is generating revenue and knowledge through both licensing of its IP portfolio and advancement of R&D projects. It already has patents and multiple patents-pending in more than 40 countries. It has received patent approvals in the U.S. and Australia for its DehydraTECH™ delivery technology (http://cnw.fm/WIdR3). Some patent applications have already reached the active patent investigation phase in China, the European Union and Canada.

LXRP is a technology disruptor for delivery of edible forms of cannabinoids. This Kelowna, British Columbia-based food bioscience company has developed a high absorption hemp oil formula, protein energy bars, exotic teas and coffee, beer and soft drinks, and capsules and mouth-melts. All of these products share qualities of high absorption and radically improved taste, as compared to other cannabis-related food products.

The Canadian Institutes of Health Research has secured $1.4 million in funding for Canadian cannabis research projects (http://cnw.fm/DeM9h). That will fund research ranging from the potential impacts of cannabis on driving, pregnancy, childhood health, youth mental health, indigenous populations and workplace health and safety (http://cnw.fm/gTE4r).

LXRP itself has signed a C$250,000 collaborative research agreement with the National Research Council (“NRC”) for an 18-month period to investigate opportunities and determine the best methods for processing lipophilic active agents within foods.

Licensing its intellectual property portfolio is a core revenue generation strategy for LXRP (http://cnw.fm/pmF79). For example, the company’s disruptive new DehydraTECH technology is available to be licensed in areas including processed foods, supplements, vitamins, drugs and cannabinoids. To prospective licensees, LXRP can eventually transition to a definitive fee for a structure agreement between itself and a new licensee.

The company makes its technology available on either a semi-exclusive or exclusive access basis that defines licensing by geographic region(s), for a set period of time and limited to specific product categories. LXRP has suggested that it will license DehydraTECH in any of the more than 40 countries globally where it is patented or patent-pending.

For more information, visit the company’s website at www.LexariaBioscience.com

More from CannabisNewsWire

About CannabisNewsWire

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Pressure BioSciences Inc. (PBIO) Just Might Have the Ideal Drug Delivery Technology for Cannabinoids

The tide of cannabis legalization continues to rise
Medical cannabis market on pace to hit $56 billion in seven years
Company’s proprietary technology improves the bioavailability of cannabinoids

With the passage of laws permitting medicinal use of cannabis in at least 32 U.S. jurisdictions and Canada, producers of cannabinoids for medical purposes are racing to improve delivery methods for their formulations. Cannabinoids, such as cannabidiol (CBD), are hydrophobic (literally, afraid of water). In practice, this means they do not dissolve or emulsify readily in water, which may seem to pose a problem, since, by composition, the human body is more than half water. Yet, paradoxically, for a drug to be readily absorbed, it must be largely hydrophobic, yet not completely so. It must, to some extent, dissolve in water. As a result, new, patented technology from Pressure BioSciences Inc. (OTCQB: PBIO) may provide the ideal transport for CBD and other cannabinoids. PBIO’s Ultra Shear Technology (“UST”) has the capacity to develop water-soluble nanoemulsions that can be employed to improve the bioavailability of cannabinoids.

Emulsions are mixtures of two or more liquids (e.g., oils in water) that cannot be blended into each other without the addition of chemicals called emulsifiers (e.g., surfactants). Emulsions are used in multiple everyday products, including food, medical products, pharmaceuticals, nutraceuticals, cosmetics, industrial lubricants, and even cannabis oil extracts (e.g., CBD). Nanoemulsions have been shown to have improved absorption while providing higher bioavailability, greater stability and other advantages, when compared to the standard, much larger macro- and micro-emulsions.

Nanoemulsions offer an advanced mode of drug delivery that’s expected to improve the bioavailability of a wide range of active agents. These nano-sized emulsions, in which two immiscible liquids are usually combined to form a single phase by means of an emulsifying agent that combines surfactant and co-surfactant, typically have droplet sizes that fall in the 20–200 nanometer range. It would take 10 million nanometers to cover a length of one centimeter (about 0.4 inches).

Interestingly, PBIO believes that its patented UST may be able to make commercial-scale nanoemulsions that would require far less emulsifying agents than current methods, perhaps even none. Emulsifying agents are chemicals; some are natural, some are not. With consumer demands for non-additive natural products, the availability of nanoemulsions that require little or no chemical emulsifiers should be well received by consumers and manufactures alike, and rewarded by shareholders.

Late last year, PBIO announced a partnership with Phasex Corporation. The aim of the collaboration is to combine PBIO’s patented UST and Phasex’s supercritical fluid (“SCF”)-based processing methods to enable the development of stable, water-soluble nanoemulsions of nutraceuticals, including CBD-enriched plant oil. Phasex is a pioneer in the development of SCF-based toll processors, which are used for extracting, purifying, recrystallizing and fractionating a wide range of polymers, natural extracts and other chemicals.

Complementing Phasex’s SCF extraction technology with PBIO’s UST makes a great deal of commercial sense. Currently, there is a market for new methods of turning hydrophobic extracts into stable, water-soluble formulations. UST offers the potential to solve that problem by producing stable nanoemulsions of oil-like products in water. The range of commercial applications is extensive and includes inks, industrial lubricants, cosmetics, pharmaceuticals and nutraceuticals, as well as medically important plant oil extracts such as CBD. UST utilizes ultra-high pressure-driven fluid dynamic shear forces, combined with controlled temperatures, to engender homogenization.

Data from scientific studies indicate that nanoemulsions of nutraceuticals and pharmaceuticals may exhibit improved absorption, higher bioavailability, greater stability and lower levels of stabilizing additives (surfactants) when compared to the larger droplet sizes resulting from current emulsion processes. Because of these significant advantages, nanoemulsions are currently the focus of many research efforts worldwide. In this field, the PBIO-Phasex joint venture is poised to break new ground. Combining Phasex’s SCF extraction methodology with PBIO’s disruptive drug delivery technology may signal the genesis of an entirely new paradigm in therapeutic treatments.

The global medical marijuana market is set to reach a value of $55.8 billion by 2025, according to a new report by Grand View Research, Inc. As it expands, the demand for enabling medical technologies, such as UST, is set to rise. PBIO, it seems, is about to thrive in the brave new world of cannabis liberalization.

For more information, visit the company’s website at www.PressureBioSciences.com

More from CannabisNewsWire

About CannabisNewsWire

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Medical Cannabis Payment Solutions (REFG) CEO Confident About Utah Cannabis Bill Success

Proposed legislation would be more moderate than a current legalization initiative but allow more concessions than a more conservative bill submitted this season
Jeremy Roberts is confident the yet undrafted bill will be ready for consistent debate before the end of the current legislative session on March 8
Cannabis is illegal in Utah, with only one exception: non-psychoactive medical CBD oil extract is allowed for patients suffering from severe epilepsy

A medical cannabis bill that would advocate a more moderate approach and would “bridge the gap” between two very different legalization initiatives currently underway, has every chance to be successful, according to Medical Cannabis Payment Solutions (OTC: REFG) CEO Jeremy Roberts, quoted by the Deseret News (http://cnw.fm/lEm4n). Roberts, who is also a member of the Utah Republican Party, discussed the matter with Rep. Lee Perry, who is planning on coming up with a “workable medical marijuana program in the state.” While the bill has not yet been formally drafted, with Perry still gathering input on language and contents, Roberts is confident that the initiative will be ready in time to be debated before the end of the legislative session on March 8.

Leveraging his experience as CEO of a merchant processing pioneer in the medical cannabis industry, Roberts said he met with several interested lawmakers in recent months to discuss what would be a “reasonable program” with appropriate controls in place to allow patients access to marijuana-based medication they need. Talks even focused on aspects of current marijuana legislation in other states, to determine which policies would make the most sense for Utah.

Cannabis is illegal in Utah, with the exception of a non-psychoactive medical CBD oil extract for patients with severe epilepsy. Advocates of medical marijuana legalization for people with serious medical conditions are rallying for a state-wide ballot sometime this year, an initiative that enjoys overwhelming support. About 76 percent of Utah voters are in favor of the initiative, according to a January survey by The Salt Lake Tribune and the Hinkley Institute of Politics with the University of Utah (http://cnw.fm/6stLQ). Opponents of the initiative, including Perry and Roberts, say the ballot goes further than most people realize and would basically provide backdoor access to the equivalent of a recreational program.

On the other side, Rep. Brad Daw has introduced a package of bills on medical marijuana which would allow terminally ill patients to try the substance and would have the state grow its own plant. Roberts believes the legislation proposed by Daw this session is too conservative, and not too different from the “ultra-conservative” initiatives that the legislature has come up with up to this point.

Lawmakers know that they need to pass a medical marijuana bill but “they haven’t been given a good option” so far, Roberts said. The Medical Cannabis Payment Solutions CEO is confident that what Perry will come up with be viewed as a better and more moderate option which the caucuses are going to love. The bill will most likely start by allowing unrestricted access to CBD oil to all patients who need it, and broad access to marijuana for terminally ill patients. Gradually, the bill will allow for higher ratios of THC to CBD for certain categories of patients, but it will most likely not allow access to the whole plant at any point, Roberts explained.

In a separate interview with Jane King of SCN Corporate Connect (http://cnw.fm/7Vul5), Roberts talked about his company’s commitment to regulatory compliance, as opposed to other companies in the industry which would rather “walk away” than put in the work to meet the federal government’s very strict guidelines and regulations. He said that part of his activity in Washington DC includes working with the authorities to show that “people actually can and are willing to comply with the regulations they put forth.”

Roberts also briefly discussed his company’s fully secure, state-of-the-art services to the medical marijuana sector, in particular its ability to track sales and tax collection from the moment when a buyer enters the vendors’ establishment, the purchases made, all the way through the payment of taxes. This functionality “hasn’t existed up until we’ve come to the marketplace, and we can actually show the provenance of funds in that market,” he said.

Medical Cannabis Payment Solutions brought to the market the first and only comprehensive card processing service. Via Green, a proprietary payment system that was launched earlier in January 2018, the company aims to offer a “cure for the banking nightmare cannabis establishments face,” according to Roberts. The platform has full merchant account functionality that allows for repeat billing, online sales, client management and 100 percent secure electronic payments. The system is also fully compliant with Financial Crimes Enforcement Network (FinCen) regulations and parameters for financial institutions serving the medical cannabis sector.

For more information, visit the company’s website at www.REFG.co

More from CannabisNewsWire

About CannabisNewsWire

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Pivot Pharmaceuticals Inc. (PVOTF) Provides Update Covering Recent Achievements and Activities

Update highlights proposed acquisitions, product development and growing IP portfolio
Three new patent filings join established global rights to other patented technologies
Innovative transdermal delivery technology increases bioavailability of cannabinoids
Global cannabis market projected to reach $31.4 billion by 2021

Pivot Pharmaceuticals Inc. (OTCQB: PVOTF) has provided investors an update covering a number of recent achievements and ongoing activities, including the company’s proposed acquisitions of ERS Holdings, LLC and Thrudermic, LLC; its ongoing product development efforts; its growing IP portfolio; its termination of a previously announced standstill agreement; out-licensing of its IP; and its engagement of an established European distribution partner (http://cnw.fm/sB649). In a news release, Dr. Patrick Frankham, CEO of Pivot, stated, “We are overwhelmed by interested companies who now understand that derivatives and superior formulations will improve cannabis product experience and healthy outcomes.”

Based in Vancouver, Canada, Pivot Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using proprietary drug delivery platform technologies. By developing and commercializing a number of pharmaceutical-grade formulations for cannabinoid-based consumer health care products, Pivot Pharmaceuticals is positioning itself to capitalize on the impressive growth of the cannabis market. According to market research company Brightfield Group, the marijuana market will experience a CAGR of 60 percent to reach $31.4 billion by 2021 (http://cnw.fm/8Kg16).

As part of its overall growth strategy, Pivot Pharmaceuticals recently filed three provisional patents for cannabinoid-based product delivery with the U.S. Patent and Trademark Office, according to a company press release (http://cnw.fm/J3CsB) issued on February 1, 2018. Its three patents cover:

Transdermal nanotechnology delivery of cannabis using patches and creams
Mucus topical cannabis delivery through buccal, nasal, vaginal and anal areas using a gel, mouthwash or suppository
Inhalation delivery of cannabis for topic or systemic applications

These latest provisional patent filings join an established number of global rights to topical, oral, transdermal, food and beverage patented technologies that Pivot has already secured.

A case in point is Pivot’s recent acquisition of the BiPhasix™ Transdermal Drug Delivery technology for the delivery of cannabinoids. Oral delivery of cannabinoids can produce inconsistent absorption efficiencies and unfavorable side effects, while topical delivery technologies often suffer from weak formulation issues. By contrast, transdermal delivery has greater potential to produce a more favorable outcome without the negative side effects and absorption issues. Another benefit of transdermal delivery is that it enables patients to apply medication over a prolonged period with fewer side effects than with other methods of delivery. The BiPhasix™ delivery system, thoroughly tested in clinical trials approved by the FDA and EMA, was demonstrated to enhance the bioavailability of drugs and to improve clinical outcomes.

Pivot Pharmaceuticals also created subsidiary Pivot Green Stream Health Solutions Inc. to focus on improving the bioavailability of cannabinoid-based pharmaceuticals. Pivot Green Stream will develop natural cannabinoid-based health products that qualify for the Natural Health Product (NHP) designation conferred by Health Canada.

In addition, Pivot has acquired the global rights from Solmic GmbH for the development and commercialization of the Solmic Solubilization Technology Platform. This formulation technology provides significantly higher bioavailability of active ingredients while masking unpleasant tastes and smells. This oral delivery platform greatly increases uptake of fat-soluble ingredients from the gut into the blood system, resulting in increased bioavailability.

The company has several products in its development pipeline which target cancer supportive care, pain and inflammation, dermatology and eye disease. They include PGS-N005, a cannabinoid-based topical cream to treat female sexual dysfunction. This formulation will treat hypoactive sexual desire disorder, aimed specifically at peri-menopausal, menopausal and post-menopausal women with a decline in sexual desire and response. It is estimated that up to 63 percent of women in the United States may be affected by this disorder, with the female sexual dysfunction market estimated to exceed $4 billion.

Pivot Pharmaceuticals has a seasoned management team with extensive clinical, product development, commercial and financial experience. The company has positioned itself to be a crucial vertical in the cannabis industry, with a focus on biotechnological development. As part of its business strategy, Pivot works with licensed producers (LPs) and licensed dealers (LDs) to bring new therapies to the market.

For more information, visit the company’s website at www.PivotPharma.com

More from CannabisNewsWire

About CannabisNewsWire

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Marijuana Company of America, Inc. (MCOA) Executing a Strategy Aligned with Future Forces

WHO recommends that CBD not be a controlled substance
Operations at various points in the cannabis and industrial hemp industries
Launch of new products for convenience stores

Two major trends are fostering the success Marijuana Company of America, Inc. (OTC: MCOA) is having. With 29 states and the District of Columbia now permitting the use of cannabis for either medicinal or recreational purposes and public stigma surrounding cannabinoids fast fading, the cannabis and cannabidiol (CBD) industry is moving toward a maturity that will make it an economic sector to be reckoned with. At the same time, an increasingly health-conscious American public is discovering the benefits of hemp-derived CBD, which, unlike delta-9-tetrahydrocannabinol (THC), is devoid of psychotropic properties.

The company, established in 2015 in California by Don Steinberg and Charles Larsen, is set to execute its vision of creating a diverse portfolio of cannabis- and hemp-based businesses. MCOA has already established a commanding presence at various points in the cannabis and industrial hemp markets, as well as the related services supply chains.

Meanwhile, MCOA’s wholly owned subsidiary, hempSMART™, Inc., continues its mission of bringing high quality hemp-derived CBD-based products to market through its affiliate marketing program. Its patent-pending product, hempSMART Brain, is designed to provide safe and effective support of healthy brain function, and its recently launched hempSMART Full Spectrum Drops offer a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. Moreover, in December 2017, MCOA announced the debut of a new personal care product: hempSMART Pain Cream (http://cnw.fm/MNf1P), and hempSMART Pain Capsules are formulated with 10mg of full spectrum, non-psychoactive CBD per serving, derived from industrial hemp as the core ingredient, which, along with a proprietary blend of other natural ingredients, delivers an all-natural formulation.

MCOA has also partnered with the founders of HoneyB Healthy Living to develop Convenient Hemp Mart, LLC’s BeniHemp branded products targeting convenience stores, according to a recent news release (http://cnw.fm/ZvY2C). MCOA has invested $100,000 into the start-up project in exchange for a 25 percent equity stake.

Now that the Expert Committee on Drug Dependence (ECDD) of the World Health Organization (WHO) has officially recommended that ‘cannabis compound cannabidiol (CBD) not be internationally scheduled as a controlled substance’ (http://cnw.fm/Dm1Um), MCOA looks set for success in the fast developing cannabis and industrial hemp CBD markets.

For more information, visit the company’s website at www.MarijuanaCompanyofAmerica.com

More from CannabisNewsWire

About CannabisNewsWire

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Earth Science Tech, Inc. (ETST) Launches High Grade Full Spectrum Cannabinoid Products

ETST intends to make 2018 its breakout year, seeks uplisting to the OTCQB Venture Market
Company manufactures using European CO2 extraction process with organically grown, unfiltered industrial hemp
ETST engages a new distributor to market revamped product line to major retailers, also adds several new members to its executive team

On February 13, Earth Science Tech, Inc. (OTC: ETST) officially launched its High Grade Full Spectrum Cannabinoids products and a corresponding marketing strategy, as the company detailed in a recent news release (http://cnw.fm/NnrI0). Additionally, it signed a distribution agreement with Mr. Checkout to market its revamped product line to major retailers and stores, such as Walmart, Target and Walgreens (http://cnw.fm/HKXq1).

The revamped line consists of industrial hemp product formulated as a cannabinoid complex, which is naturally occurring in the industrial hemp plant and is rich in terpenes and saponins. The company’s products are mixed, bottled and packaged in the U.S., and reorders are currently being accepted online. The line appears in modern and edgy packaging.

Based in Florida, ETST markets high-purity, high-grade hemp cannabidiol (CBD) oil. It is 100 percent natural and organic. The company has three wholly-owned subsidiaries: Earth Science Pharmaceutical markets low-cost, non-invasive medical devices for the detection of sexually transmitted diseases (STDs); Cannabis Therapeutics is an emerging biotechnology company; and KannaBidioiD focuses on the recreational space with its hemp and Kanna blends.

ETST recently strengthened its core executive team (http://cnw.fm/mRBR4) through the addition of Jill Buzan as chief sales officer, Wendell Hecker as chief financial officer and Gabriel Aviles as chief learning officer. The company expects the moves to foster bottom line growth in 2018.

In a news release, Nickolas S. Tabraue, COO and president of ETST, said, “Between appointing a new Chief Sales Officer, launching revamped industrial hemp products with fresh branding and marketing strategies, and our new distributor, Mr. Checkout, we are on track for a record-setting revenue month.” He added that the company intends to make 2018 its breakout year, for which it is laying a strong foundation in the first quarter.

The company also announced that it has completed the paperwork for its uplisting to the OTCQB Venture Market later this year.

For more information, visit the company’s website at www.EarthScienceTech.com

More from CannabisNewsWire

About CannabisNewsWire

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Strategic Partnerships Elevate The Green Organic Dutchman’s Premium Cannabis To Heady Future

Closing of $112 million in private placement financing fully funds expansion plans
Time-to-market accelerated as Aurora Cannabis inks strategic investment/partnership with TGOD
Highly anticipated IPO scheduled for March 2018
Organic, medical-grade cannabis grown at low cost increases profit margins

The Green Organic Dutchman Holdings Ltd. (“TGOD”) continues to make headlines as it forms strategic partnerships and banks investment funds to fuel the company’s expansion plans to become the largest organic cannabis company in the world. The company’s recent announcement of its closing of $112 million in private placement financing included a cornerstone investment of $55 million by marijuana industry powerhouse Aurora Cannabis Inc. (OTCQX: ACBFF) (TSX: ACB) (http://cnw.fm/5lHaB). To date, TGOD has raised $160 million with over 4,000 shareholders.

TGOD is setting the industry standard on several fronts, including environmental stewardship, natural resource sustainability and development of a consortium of world-class architectural, construction and utility management teams dedicated to responsible practices. As a Canadian licensed cannabis producer, TGOD prides itself on growing completely organic, pesticide-free, grown-in-live-soil cannabis. In an interview with Equities.com (http://cnw.fm/uL0cG), Danny Brody, TGOD’s vice president of investor relations, said that he believes the company’s commitment to growing medical grade cannabis sets it apart.

“From day one we believed that organic product is key,” Brody stated. “That is one of our key differentiators that we will be continuing as we build out our operation.”

With this new infusion from investors, TGOD is able to fully fund a 970,000 square foot expansion of its organic cannabis production facilities located in Ontario and Quebec, two of Canada’s most populated provinces. The facilities, capable of producing 116,000 kg of cannabis annually, are slated to come online in Q4 2018 and Q2 2019, respectively. While medical marijuana has been legal in Canada since 2001 and is projected to grow to $2.1 billion by 2020, the recreational marijuana market is expected to reach $22 billion by 2024, according to a Deloitte report (http://cnw.fm/vdFR1).

The “Canadian Advantage” is real and the opportunities are unparalleled, both in Canada and internationally, as TGOD management noted in its latest corporate presentation to shareholders. As the first G7 nation poised to legalize recreational marijuana use, Canada is having a profound impact on legalization efforts around the world. In contrast, there are 29 states in the U.S. that currently allow some form of marijuana use, although there are measures on several ballots that could add legal cannabis to the lawbooks in additional states in the near future (http://cnw.fm/Phxu6). John Kagia, a cannabis industry analyst for New Frontier Data, called the recent move toward Canadian legalization a “wake up call to all investors who were sitting on the sidelines, that this is really going to happen.”

Although full implementation of legal cannabis for adults in Canada is expected to be in place by July 2018, there is some waffling on the timing, as legislation allowing for recreational cannabis must still pass Parliament (http://cnw.fm/Sw33v). Health Minister Ginette Petitpas Taylor said lower levels of government have informed her that more time – as much as eight to 12 weeks – may be required following adoption of the law (http://cnw.fm/1Do8B).

Timing is important, as TGOD is proving with its recent investment news and early spring 2018 plans to transition from a privately-held company to a publicly-traded one. TGOD believes that its unique approach to producing high quality, pharma-grade cannabis, coupled with its solid commitment to core values, offers numerous opportunities for additional joint ventures, licensing and distribution partnerships for a sustainable and successful future.

For more information, visit the company’s website at www.TGOD.ca

More from CannabisNewsWire

About CannabisNewsWire

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Skinvisible, Inc. (SKVI) Products Can Offer Protection against Highly Contagious Viruses like H3N2

2018 flu season could cost U.S. businesses $15 billion in lost productivity
Winter Olympics hit with norovirus, sickening 128 Olympic workers
Centers for Disease Control and Prevention urging public to wash hands, use hand sanitizer in battle against infection
DermSafe® antimicrobial hand sanitizer is 99.9 percent effective against a list of deadly bacteria and viruses

It’s a simple phrase: “Wash your hands and use a hand sanitizer,” but doing it correctly and with the right product can make the difference when it comes to protection against a nasty bacteria or virus. Using an antiseptic hand sanitizer lotion such as DermSafe®, which incorporates Skinvisible’s (OTCQB: SKVI) proprietary Invisicare® drug delivery technology, is another vital tool offering a barrier against potentially serious illnesses. Skinvisible Pharmaceuticals, Inc., developer of over 40 topical prescription, over-the-counter and cosmeceutical products using its patented Invisicare® polymer delivery systems, donated over 1,000 bottles of DermSafe® to the Canadian Olympic team for the 2016 Summer Games in Rio (http://cnw.fm/kP2Zb), the company has now sent the same supply for the Olympic team in South Korea for the 2018 Winter Games. It’s a timely donation and one that could make a significant difference to the welfare of the team.

In fact, every athlete at the 2018 Winter Olympic Games in Pyeongchang, South Korea, is taking extra precautions to stay healthy, especially after an outbreak of the highly contagious norovirus sickened more than 120 security staff and others, prompting organizers to deploy 900 military personnel to assist at the games (http://cnw.fm/xQ8m0). Even more alarming is the continuing number of deaths resulting from an aggressive influenza strain – H3N2 – affecting children and adults living in the continental United States (http://cnw.fm/z3RTl). The common thread running throughout all of these stories is an admonition from health care professionals urging the public to religiously “wash your hands” and use hand sanitizers. Germs can live on any surface, so washing hands and wearing an antimicrobial hand lotion like DermSafe® is one of the best ways to stop germs from hitching a ride (http://cnw.fm/27iFH).

One application of DermSafe provides a four-hour protective barrier that binds to the skin and actively combats the spread of germs between people and hard surfaces. The active ingredient is four percent chlorhexidine gluconate (CHG), the same active ingredient found in soaps used in hospital operating rooms. DermSafe offers long-term protection and destroys both gram-negative and gram-positive bacteria and viruses (http://cnw.fm/8jRb6). It has been tested and proven effective against a host of infectious germs, including Methicillin-resistant Staphylococcus aureus (MRSA), Escherichia coli (E. coli) and salmonella. Sales of DermSafe have already taken off in China, and the product will be marketed throughout the country.

This year’s flu outbreak could conceivably cost U.S. businesses anywhere from $15 billion to $21 billion in lost productivity, Andrew Challenger, vice president of global employment consulting firm Challenger, Gray & Christmas, Inc., said in a 2017-2018 Flu Season report (http://cnw.fm/u9cAg). The agency raised itd earlier estimates by 64 percent, stating the 2018 flu virus could cause more than 18 million U.S. employees to miss at least four 8-hour shifts.

“Sick workers may think they are doing the right thing by ‘toughing it out’ and coming into work when they feel ill,” Challenger said in a news article (http://cnw.fm/S1CJs). However, “they are only likely to spread their illness, potentially further interrupting optimum business operations.”

Prevention and protection is the key when it comes to avoiding infectious germs. Although this season’s flu strain is particularly vicious, experts continue to remind the public that washing hands often and applying a long-term, antimicrobial hand sanitizer such as Skinvisible’s DermSafe® offers scientifically-proven protection against bacteria and viruses.

For more information, visit the company’s website at www.Skinvisible.com

More from CannabisNewsWire

About CannabisNewsWire

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

AV1 Group, Inc. (AVOP) Announces Engagement of Strategic Corporate Advisor to Assist in Propelling LED Division

Jon Fortune joins AV1 as strategic corporate advisor
LED lighting is cost- and energy-efficient for companies, homes and grow houses
X-Fire Smart Systems™ is an innovative solution for smart cities and homes

AV1 Group, Inc. (OTC: AVOP) recently announced the addition of Jon Fortune to its team. In a news release, AV1 Group CEO Bryen Beglinger stated, “We welcome Jon to our team. He has a wealth of experience and with his expertise in renewable energy, he will be a significant asset. He has a number of contacts in the industry that he is already working with on co-development opportunities, solutions and building customer relationships for our LED division and Smart City projects. Jon will also be working with our wholly-owned subsidiary, X-Fire, Inc., to incorporate block chain technology to the current product offering.”

AV1 Group explores every opportunity to help each sector exceed revenue goals. Each division is prepared to be a strong competitor in its given market. Engaging strong contenders, like Fortune, is a strategic move toward the success of AVOP, as multiple subsidiaries are created under one umbrella.

The LED Division provides cost- and energy-efficient lighting solutions for companies, homes and grow houses. The long-lasting LED lighting is attractive to lighting designers and property managers and is sold under the subsidiary Intelligent Lighting Corp. Growth Spectrum™ is a product line marketed to the cannabis industry. A strategic partnership with the LED manufacturer allows the company entry into a fast-growing market with minimal overhead. CannaLighting™ is actively building strategic relationships in the LED sector to potentially provide solutions to a rapidly increasing number of grow houses and cultivation centers. LED lighting solutions are an important factor for these indoor agricultural environments.

X-Fire Smart Systems™ is part of AVOP’s innovative solutions for city smart grids, home and business lighting and ecommerce. Through this subsidiary, the company offers a range of smart technology. The Apollo LED Series is an intelligent lighting solution with the ability to provide street-wide wireless access. It is an all-in-one housing that incorporates a wireless MESH radio for secure remote access and monitoring of infrastructure. It allows for programmable diming schedules and motion or light sensors. Smart parking meters allow for the use of credit cards instead of quarters. Charging stations integrate to allow authorization of credit cards and report usage to power providers. Digital utility meters provide time and cost savings and better customer service, and the Apollo Picocell extends cellular coverage to places where there is no signal. Picocells provide coverage, capacity and cost savings in areas that can be difficult to reach.

Fortune promises to be a significant asset as AVOP continues to seek out existing hardware, software designers and manufacturers in the LED and smart city industries.

For more information, visit the company’s website at www.AV1Group.com

More from CannabisNewsWire

About CannabisNewsWire

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net